Omniome

Very low-cost genomic and proteomic sequencing in silicon

First Investment: 2014

EXIT - Acquisition (Pacific Biosciences: PACB)

Omniome developed a proprietary DNA sequencing platform that delivered more accurate short reads than competing systems. Pacific Biosciences acquired the company in 2021.

News & Insights

Thoughts

Big Data Strikes Back: The Rise of Image, Sensor, and Genome Data Powering Deep Vertical Startups

Explore Companies

Grove Biopharma

Putting protein-like drugs inside cells to fight cancer and neurodegeneration

Syntax Bio

Programming stem cells to differentiate into desired cell types, faster

Fable Therapeutics

Using state-of-the-art machine learning models to create custom-build protein drugs

Nilo Therapeutics

Mapping the brain-body axis to achieve proper immune balance